1. Cell Cycle/DNA Damage
    Cytoskeleton
    Autophagy
  2. Microtubule/Tubulin
    Autophagy

Colchicine 

Cat. No.: HY-16569 Purity: 99.56%
Handling Instructions

Colchicine is a tubulin inhibitor and a microtubule disrupting agent. Colchicine triggers apoptosis.

For research use only. We do not sell to patients.
Colchicine Chemical Structure

Colchicine Chemical Structure

CAS No. : 64-86-8

Size Price Stock Quantity
10 mM * 1 mL in DMSO $55 In-stock
200 mg $50 In-stock
500 mg $65 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Colchicine is a tubulin inhibitor and a microtubule disrupting agent. Colchicine triggers apoptosis.

IC50 & Target

Microtubule/Tubulin[1]

In Vitro

Exposure to 1μM Colchicine, a microtubule disrupting agent, triggered apoptosis in rat cerebellar granule cells (CGC). Colchicine treatment also causes alterations in Ca2+ responses to chemical depolarization and a moderate, but progressive, increase in the resting intracellular Ca2+ concentration[1]. Colchicine exerts its biological effects through binding to the soluble tubulin heterodimer, the major component of the microtubule. The Colchicine binding abilities of tubulins from a variety of sources are summarized, and the mechanism of Colchicine binding to brain tubulin is explored in depth. The relationship between colchicinoid structure and tubulin binding activity provides insight into the structural features of Colchicine responsible for high affinity binding to tubulin and is reviewed for analogs in the Colchicine series. The thermodynamic and kinetic aspects of the association are described and evaluated in terms of the binding mechanism. Colchicine binding to tubulin results in unusual alterations in the low energy electronic spectra of Colchicine. The spectroscopic features of Colchicine bound to tubulin are discussed in terms of the nature of the Colchicine-tubulin complex. Attempts to locate the high affinity Colchicine binding site on tubulin are presented[2]. Colchicine treatment inhibits indomethacin-induced small intestinal injury by 86% (1 mg/kg) and 94% (3 mg/kg) as indicated by the lesion index 24 h after indomethacin administration. Colchicine inhibits the protein expression of cleaved caspase-1 and mature IL-1β, without affecting the mRNA expression of NLRP3 and IL-1β[3].

In Vivo

Vehicle or Colchicine (1 mg/kg) is administered orally 30 min prior to indomethacin administration. The lesions stained with Evans blue in the small intestine are smaller in Colchicine-treated mice than those in vehicle-treated mice 24 h after indomethacin administration. In addition, histological examination shows that Colchicine-treated mice have less mucosal inflammation and ulceration and a decrease in the size and numbers of lesions compared with vehicle-treated mice. Colchicine treatment significantly reduces the lesion index at doses of 1 mg/kg and 3 mg/kg (by 86% and 94%, respectively) compared with vehicle treatment. Colchicine treatment significantly inhibits the protein levels of mature IL-1β at doses of 1 mg/kg and 3 mg/kg (by 56% and 69%, respectively) without affecting those of pro-IL-1β. Colchicine treatment also significantly inhibits the protein levels of cleaved caspase-1 at doses of 1 mg/kg and 3 mg/kg (by 26% and 39%, respectively) without affecting those of pro-caspase-1[3].

Clinical Trial
Sponsor Condition Start Date Phase
McMaster University Atrial fibrillation 2014-01-31 Phase 3
Azienda Sanitaria Locale 3, Torino Pericardial disease 2005-06-30 Phase 3
Shaheed Beheshti Medical University 2006-09-30 Phase 3
Maria Vittoria Hospital Atrial fibrillation 2012-03-31 Phase 3
Sanofi Tonsillitis 2006-10-31 Phase 3
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 2.5035 mL 12.5175 mL 25.0350 mL
5 mM 0.5007 mL 2.5035 mL 5.0070 mL
10 mM 0.2504 mL 1.2518 mL 2.5035 mL
Animal Administration
[3]

Colchicine is prepared in DMSO and diluted with saline or PBS[3].

Mice[3]
Specific-pathogen-free 8-week-old male mice are used. Wild-type C57BL/6 mice and NLRP3−/− mice on a C57BL/6 background are used. To examine the effects of Colchicine on NSAID-induced small intestinal injury, vehicle or Colchicine (1 or 3 mg/kg) is administered orally 30 min prior to indomethacin administration. Mice received intraperitoneal injections of sterilized phosphate buffered saline or mouse recombinant IL-1β (0.1 μg/kg) 3 h after indomethacin treatment. Vehicle or Colchicine (1 or 3 mg/kg) is also administered to NLRP3−/− mice before indomethacin administration. The lesion index is evaluated 24 h after indomethacin administration, and examined mRNA and protein expression of inflammasome components 6 h after indomethacin administration.

References
M.Wt

399.44

Formula

C₂₂H₂₅NO₆

CAS No.

64-86-8

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 48 mg/mL

Purity: 99.56%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Colchicine
Cat. No.:
HY-16569
Quantity: